Table 1

Baseline characteristics of the included patients separated in non-progressors and progressors

Baseline characteristicsTotal N=492Non-progressors, N=235Progressors, N=257
Demographics
Female, n (%)389 (79)193 (82)196 (76)
Age, mean (SD)55 (14)55 (15)55 (13)
Disease duration non-RP, median (IQR)3.2 (0.9–10.3)3.5 (0.8–10.5)3.6 (1.1–9.3)
 lcSSc, median (IQR)4.1 (1–11)3.9 (1–11)2.4 (1–11)
 DcSSc, median (IQR)3.0 (1–8)2.7 (1–7)4.1 (0.5–9)
Organ involvement
DcSSc, n (%)118 (24)34 (15)84 (33)
mRSS, median (IQR)4 (0–6)2 (0–5)4 (1–7)
DU, n (%)62 (13)29 (12)33 (13)
DLCO% of pred, mean (SD)66 (18)69 (18)64 (17)
FVC% of pred, mean (SD)98 (23)96 (24)97 (21)
ILD on HRCT, n (%)183 (37)66 (28)117 (46)
PAH, n (%)26 (5)10 (4)16 (6)
GAVE, n (%)9 (2)4 (2)5 (2)
Cardiac involvement, n (%)28 (6)14 (6)14 (5)
Myositis, n (%)8 (2)6 (3)2 (1)
Renal crisis, n (%)14 (3)6 (3)8 (3)
Autoantibodies
Anticentromere, n (%)194 (39)118 (50)76 (30)
Antitopoisomerase, n (%)116 (24)42 (18)74 (29)
Medication (current use)
Corticosteroids, n (%)42 (9)16 (7)26 (10)
Methotrexate, n (%)68 (14)34 (15)34 (13)
Mycophenolate mofetil, n (%)19 (4)5 (2)14 (5)
Hydroxychloroquine, n (%)22 (5)7 (3)15 (6)
Cyclophosphamide, n (%)11 (2)4 (2)7 (3)
Azathioprine, n (%)14 (3)2 (1)12 (5)
ASCT, n (%)4 (1)2 (1)2 (1)
  • Bold indicates significant differences p<0.05 between progressors versus non-progressors.

  • ASCT, autologous stem cell transplantation; dcSSc, diffuse cutaneous systemic sclerosis; DLCO, diffusing capacity of the lungs for carbon monoxide; DU, digital ulcers; FVC, forced vital capacity; GAVE, gastric antral vascular ectasia; HRCT, high resolution CT; ILD, interstitial lung disease; mRSS, modified Rodnan skin score; PAH, pulmonary arterial hypertension; RP, Raynaud’s phenomenon.